CHMP adopts a positive opinion of nivolumab + ipilimumab as 1st line treatment
Press release: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with... Read More
Kidney Cancer patients suffer high levels of stress
Distress Levels High Among Patients With Common Form of Kidney Cancer Many patients with renal cell carcinoma, the most common type of... Read More
Phase 2 of study reports smaller tumors
AVEO Pharmaceuticals and EUSA Pharma said the Phase 2 portion of a study evaluating a treatment for renal cell carcinoma, the most common... Read More
Contrast-enhanced ultrasound aids diagnosis of kidney cancer
An enhanced ultrasound scan of the kidney is more accurate than computed tomography and magnetic resonance imaging in predicting cancer. A 10-year... Read More
cabozantinib, new first line treatment for kidney cancer
Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or... Read More
Discovery of kidney cancer driver could lead to new treatment strategy
In a study published in the journal Science, researchers led by UNC Lineberger’s Qing Zhang, PhD, suggest that ZHX2 is a potential... Read More
How ablation destroys cancer to prolong lives
A very interesting article in The Guardian (7th August 2018) relating to a much underused treatment for kidney cancer in the UK, Ablation.... Read More
A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer
Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer. In what... Read More
Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC
OncLive reports that a trial in the USA of novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx)... Read More
Be Clear on Cancer
Kidney Cancer UK are proud to be partnering with Public Health England on their 2018 Be Clear on Cancer campaign which calls for people to “tell their doctor” if they notice blood in their pee.
Kidney cancers caught stealing genes from other cell types in order to spread
The study, led by scientists from the MRC Cancer Unit at the University of Cambridge, suggests that this may also help to... Read More
Cabozantinib Effective in Real-World Analysis for Relapsed Mrcc
Cabozantinib is a safe and effective treatment option for patients with relapsed renal cell carcinoma (RCC) in every clinical practice, according to... Read More
Melinda Whale loses her battle with cancer
Nick Turkentine and everyone at Kidney Cancer UK are deeply saddened at the news that Melinda Whale has lost her courageous fight... Read More
CABOSUN trail shines for Cabozantinib
New CABOSUN Data Show Better PFS With Cabozantinib in mRCC Read the full article HERE Updated results from the phase II CABOSUN... Read More
Nivolumab Dosing Schedules Approved for Europe
A 4-week dosing schedule for nivolumab (Opdivo) has been approved by the European Commission for the treatment of patients with advanced melanoma... Read More
Welding World Awards 2018 raises over £10,000
Kidney Cancer UK were delighted to be the beneficiary of the The Welding World Awards 2018 Gala dinner on Wednesday 11th April. Alice... Read More
Preliminary results for avelumab + axitinib..
…. as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial... Read More
Nivolumab approved for monthly use in USA
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every... Read More
NICE recommends tivozanib as first-line treatment for advanced renal cell carcinoma
EUSA Pharma has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending... Read More
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared... Read More
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup... Read More
SABR for Renal Cell Carcinoma Offers Excellent Outcomes
Stereotactic ablative radiotherapy (SABR) for patients with primary renal cell carcinoma (RCC) is well tolerated and is associated with excellent local oncologic control,... Read More
3D Printed Prostates Could Improve Preoperative Planning and Developed for RCC
Researchers have developed a new technique for 3D printing (printed) patient-specific prostate glands using polymers that accurately model a prostate’s dimensions and physical... Read More
MRI technology bypasses need for biopsy
The most common type of tumor found in the kidney is generally quite small (less than 1.5 in). These tumors are usually... Read More